An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P154
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hellmann, Matthew
Ramalingam, Suresh
Reck, Martin
O'Byrne, Ken
Paz-Ares, Luis
Harbison, Christopher T
Bhagavatheeswaran, Prabhu
Nathan, Faith
Brahmer, Julie
Article History
First Online: 4 November 2015